Onyx Pharmaceuticals, Inc. (ONXX)

NetscribeHealthC (48.79) Submitted: 2/27/07 7:54 AM : Start Price: $27.16 ONXX Score: -52.00

Changing the way Cancer is treated – is the basic philosophy behind Onyx. The company is building an oncology business by developing therapies that target the molecular mechanisms implicated in cancer. It develops oral anticancer therapies designed t...

Report this Post Replies: 0 | Reply | Permalink

JPfyr (42.76) Submitted: 2/27/07 11:21 PM : Start Price: $25.91 ONXX Score: 56.53

RX companies are risky, but I'm optimistic on their drug that works on TWO kinds of cancer

Report this Post Replies: 0 | Reply | Permalink

TMFBreakerJava (99.25) Submitted: 5/16/07 8:14 PM : Start Price: $31.84 ONXX Score: 35.93

This is a biotech company with a successful cancer drug already on the market for the treatment of kidney cancer. While sales have been slow to grow in the US, they are growing internationally. Meanwhile positive results recently revealed in a stud...

Report this Post Replies: 0 | Reply | Permalink

bsamim (94.40) Submitted: 3/08/07 8:05 PM : Start Price: $26.09 ONXX Score: 56.11

This company will eventually outpreform in the long run, as it is has both drugs for breast cancer, that although they are not truly that effective, currently only 5% in the phase 3 clinical trials as effective, the big reason to own and play this co...

Report this Post Replies: 0 | Reply | Permalink

lostbear10 (83.40) Submitted: 4/16/07 3:40 PM : Start Price: $26.75 ONXX Score: 55.82

This stock was an excellent choice. Bought it low and sold for a profit of 112%. Will buy again on a correction. Possible buyout candidate.

Watch this stock closely and be ready to ride any upward spikes.

Report this Post Replies: 0 | Reply | Permalink

drwings (< 20) Submitted: 10/24/06 3:56 PM : Start Price: $18.58 ONXX Score: 111.81

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative therapies that target the molecular mechanisms that cause cancer. The company is developing Nexavar®, a small molecule drug, with Bayer Pharmaceuticals Corporation. Nexav...

Report this Post Replies: 0 | Reply | Permalink

DoctorsL (< 20) Submitted: 4/04/07 7:18 PM : Start Price: $25.96 ONXX Score: -58.28

This company has been such a disappointment. Major shareholders have recently sold off a large number of shares;earning estimates are down, and despite its laudable mission and its positive trial results, the stock is underperforming. It seems unlike...

Report this Post Replies: 1 | Reply | Permalink

lanhammk (83.52) Submitted: 4/13/07 7:24 PM : Start Price: $26.85 ONXX Score: 54.76

holding steady after the big move with their drug announcement.

Report this Post Replies: 0 | Reply | Permalink

not2eager (87.49) Submitted: 9/20/07 2:04 PM : Start Price: $40.91 ONXX Score: 10.53

No brainer. Will take market share from Pfizer's Sutent as oncologists start favoring one flexible brand. Combination therapies will drive Nexavar growth to multi-billion numbers. Bayer gets half - good deal for them, but very little downside risk...

Report this Post Replies: 0 | Reply | Permalink

withoutlimits (91.90) Submitted: 12/12/07 3:10 PM : Start Price: $55.53 ONXX Score: 16.36

I think it has exceed a reasonable price in the short term.

Report this Post Replies: 0 | Reply | Permalink